HK Stock Market Move | KINTOR PHARMA-B (09939) rose nearly 14% intra-day. Combined drug therapy for male pattern hair loss Ib/III clinical observational trial reached the primary study endpoint.

KINTOR PHARMA-B (09939) rose nearly 14% during intraday trading, and as of the time of writing, it had risen by 10% to HK $1.32, with a trading volume of HK $6.9331 million. On the news front, Kantor Pharma announced that the Ib/III clinical trial of KX-826 in combination with minoxidil for the treatment of androgenetic alopecia in Chinese adult men has achieved its primary endpoint. Kantor Pharma stated that based on the results of this study, the company is more confident in the potential of the patented combination therapy and will proceed with the Phase III clinical trial in an orderly manner. The announcement stated that the above clinical observation trial is an open-label, randomized controlled study designed to evaluate the effectiveness and safety of KX-826 in combination with minoxidil for the topical treatment of androgenetic alopecia in Chinese adult men. Based on the trial results, the future formal Phase III clinical trial design will be optimized, including dosage selection, number of patients enrolled, and other key elements.